secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001628280-23-014759
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q1 revenue falls 29% to $18.3B; adjusted EPS $1.23; reaffirms FY2023 guidance
--------------------------------------------------------------------------------

- First-quarter 2023 revenues $18.3B (down 29% YoY); reported diluted EPS $0.97, adjusted diluted EPS $1.23 (down 24% YoY).
- Comirnaty revenues dropped 75% operationally; Paxlovid revenues increased by $2.8B; ex-COVID products grew 5% operationally.
- FY2023 guidance reaffirmed: revenue $67-71B, adjusted EPS $3.25-3.45; midpoint implies ~31% operational revenue decline.
- Proposed acquisition of Seagen (oncology ADC) expected to close late 2023 or early 2024; integration planning underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/0001628280-23-014759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/pfe-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-014759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer